Want to see AU:CUV full AI Analyst Report?

Clinuvel Pharmaceuticals (CUV) Price & Analysis

113 Followers

CUV Stock Chart & Stats

AU$11.08

-AU$0.31(-2.63%)

At close: Jan 09 4:00 PM EST

AU$11.08

-AU$0.31(-2.63%)

Day’s Range― - ―

52-Week RangeAU$8.35 - AU$14.00

Previous CloseN/A

Volume193.84K

Average Volume (3M)97.23K

Market Cap

AU$518.40M

Enterprise ValueAU$478.64M

Total Cash (Recent Filing)AU$233.00M

Total Debt (Recent Filing)AU$341.09K

Price to Earnings (P/E)15.8

Beta0.68

Next Earnings

Sep 01, 2026

EPS Estimate

0.45

Next Dividend Ex-DateN/A

Dividend Yield0.38%

Share Statistics

EPS (TTM)0.65

Shares Outstanding50,427,900

10 Day Avg. Volume118,433

30 Day Avg. Volume97,231

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.16

Price to Sales (P/S)5.47

P/FCF Ratio12.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$28.10

Price Target Upside153.61% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.77

Revenue Forecast (FY)AU$105.43M

Bulls Say, Bears Say

Bulls Say

Strong, Debt-free Balance SheetClinuvel's large cash balance and 21-year debt-free record create durable financial flexibility. With term deposits earning ~4.5% and positive operating cash flow, the company can fund clinical programs, manufacturing scale-up and commercialization without reliance on dilution or external debt, reducing financing risk over the medium term.

Sustained ProfitabilityTwo decades of sustained profitability and record first-half sales demonstrate resilient commercial economics for SCENESSE. This track record supports self-funding of R&D and strategic initiatives, indicates operational discipline, and provides a stable base for incremental reinvestment into growth areas without immediate external capital needs.

Structural Commercial UpsideRegulatory allowance for more implants per patient and an expanded U.S. site network materially increase addressable volume and access. Higher permitted implants per patient and broader site coverage are structural demand drivers that should elevate recurring implant throughput and support more durable revenue growth per treated patient across core markets.

Bears Say

Rising Operating CostsA meaningful step-up in operating spend—across personnel, commercial distribution and R&D consumables—raises the company's fixed cost base. If revenue growth does not accelerate to match these investments, margin compression and longer payback on R&D and commercialization investments could pressure cash conversion and strategic flexibility.

Regulatory & Timing RiskClinuvel's requirement to complete specific programs before filing for vitiligo approvals, plus outstanding SEC feedback on the ADR/NASDAQ uplift, creates sequencing and timing uncertainty. These dependencies can delay regulatory approvals, market expansion and U.S. investor access, deferring expected revenue diversification and strategic milestones.

Single-Product ConcentrationRevenue remains concentrated in the single marketed product SCENESSE while newer franchises (PhotoCosmetics, peptides) are prelaunch. This concentration exposes the company to reimbursement, supply and competitive risks, and means portfolio diversification depends on successful clinical outcomes and commercial execution that are not yet proven.

Clinuvel Pharmaceuticals News

Clinuvel Files 20-F as It Pursues Nasdaq ADS Uplisting

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals has publicly filed a Form 20-F registration...

15d ago

Clinuvel Issues 887,956 Unquoted Performance Rights Under Incentive Scheme

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals has notified the market of the issue...

2M ago

Clinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. Clinuvel Pharmaceuticals is a Melbourne‑based specialty drug developer focused...

2M ago

FDA Drops QT Study Requirement for Clinuvel’s SCENESSE

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals said the U.S. Food and...

2M ago

Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel Pharmaceuticals has received final scientific advice from the...

2M ago

Clinuvel Performance Rights Lapse After Conditions Not Met

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an announcement. Clinuvel Pharmaceuticals has announced the cessation of 46,067 performance...

3M ago

Clinuvel Issues New Shares, Confirms Compliance With Disclosure Rules

An update from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals has issued 227,158 fully paid...

3M ago

Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel used the 2026 American Academy of Dermatology Annual...

3M ago

Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals is showcasing its melanocortin-based programs...

3M ago

Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel Pharmaceuticals reported its strongest first-half financial performance, maintaining...

3M ago

CUV FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest share price was AU$8.35 and its highest was AU$14.00 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is AU$518.40M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 62 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported AU$0.206 earnings per share for the quarter, missing the consensus estimate of AU$0.293 by -AU$0.087.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.38%. See more information on Clinuvel Pharmaceuticals Limited dividends here

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.45.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,427,900 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.206 in its last earnings report, missing expectations of AU$0.293. Following the earnings report the stock price went down -3.243%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:CUV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

13.29%

Trailing 12-Months

Asset Growth

22.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Clinuvel Pharmaceuticals (CUV) Earnings & Revenues

Historic Earnings Reports

CUV Company Deck

CUV Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all AU:CUV earnings summaries

CUV Stock 12 Month Forecast

Average Price Target

AU$28.10

▲(153.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"AU$8","16":"AU$16","24":"AU$24","32":"AU$32","40":"AU$40"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$39.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$28.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16,24,32,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.28,12.504615384615384,14.72923076923077,16.953846153846154,19.17846153846154,21.403076923076924,23.627692307692307,25.852307692307694,28.07692307692308,30.301538461538463,32.526153846153846,34.75076923076924,36.97538461538462,{"y":39.2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.28,11.65076923076923,13.02153846153846,14.392307692307693,15.763076923076923,17.133846153846154,18.504615384615384,19.875384615384615,21.246153846153845,22.616923076923076,23.987692307692306,25.358461538461537,26.729230769230767,{"y":28.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.28,10.796923076923076,11.313846153846153,11.83076923076923,12.347692307692308,12.864615384615384,13.381538461538462,13.898461538461538,14.415384615384614,14.932307692307692,15.44923076923077,15.966153846153846,16.483076923076922,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.071,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.668,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.17,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >